p e r s p e c t i v e
Rapid and affordable tumor molecular profiling has led to an explosion of clinical and genomic data poised to enhance the diagnosis, prognostication and treatment of cancer. A critical point has now been reached at which the analysis and storage of annotated clinical and genomic information in unconnected silos will stall the advancement of precision cancer care. Information systems must be harmonized to overcome the multiple technical and logistical barriers to data sharing. Against this backdrop, the Global Alliance for Genomic Health (GA4GH) was established in 2013 to create a common framework that enables responsible, voluntary and secure sharing of clinical and genomic data. This Perspective from the GA4GH Clinical Working Group Cancer Task Team highlights the data-aggregation challenges faced by the field, suggests potential collaborative solutions and describes how GA4GH can catalyze a harmonized data-sharing culture.
There is broad consensus that the identification of aberrations in tumor DNA is key not only to achieving a better understanding of cancer but also to developing an improved process for selecting patients for specific treatments. The latter is embraced by patients and their oncologists for the promise it holds of improving therapeutic outcomes through precision medicine, and by payers and governments because of its potential to reduce healthcare costs. Several governments and government-sponsored initiatives have recognized that linking and sharing clinical information and genomic knowledge are key requisites for delivering twenty-first-century cancer care (https:// www.whitehouse.gov/blog/2015/01/20/watch-president-obamas-2015-state-union), including the recently announced "moonshot" effort to cure cancer, endorsed by US President Obama 1 . Examples of initiatives with a clinico-genomic data-sharing aspiration include the US-based Precision Medicine Initiative and the UK's 100,000 Genomes Project, both of which have cancer as a major focus of their activities 2, 3 . The goal of these and of other projects is to show how a genomically informed understanding of diseases such as cancer can transform patient care.
To this end, many institutions worldwide have developed cancermolecular-profiling initiatives to identify relevant biological drivers and to use this information to inform biomarker-guided clinical trials. These initiatives, coupled with the increased utility of nextgeneration sequencing (NGS), compared to conventional sequencing approaches, and its ever-decreasing costs, have fueled an unprecedented expansion of genomic data generated from people with cancer. However, these efforts typically either occur at an institutional level or are compartmentalized within disease-specific activities 4, 5 . The analysis and storage of annotated genomic data in such isolated "silos" prevents collective data curation and data sharing, which makes the analysis of phenotype-genotype relationships prone to inconsistent interpretation-especially for low-frequency variants-owing to the use of different bioinformatics algorithms. A global unified approach is required to maximize our ability to recognize biological patterns between groups of patients, whose information may reside currently in different databases or institutions, and to use this knowledge to drive preventive or therapeutic interventions. The benefits afforded by data aggregation are substantial, and they would address a number of scenarios that the cancer community encounters (Box 1).
The sharing of aggregated data has thus become a substantial ratelimiting step in the development of cancer-prevention and treatment strategies. This not only has implications for patient populations with uncommon histologies or rare phenotypes, but is also increasingly relevant for cancer treatment in general, given a rise in the molecular stratification of individuals with common malignancies into smaller groups to tailor their treatment, either through drug repurposing or by using innovative precision-medicine protocols.
Although the importance of open access to genomic information is clearly recognized [6] [7] [8] [9] , multiple technical and logistical barriers for effective data sharing persist, including data noncomparability, coding heterogeneity, difficulties in the storage and transfer of large data sets and nonstandardized bioinformatics analyses. Additionally, regulatory, legal and ethical processes are not designed for global data sharing and thus require urgent attention.
In the face of this fragmented landscape, the GA4GH was established in 2013 with a vision to promote the responsible and effective sharing of genomic and clinical data and to transfer the benefits of this "team science" approach directly to patients (Box 2). In this Perspective, we highlight the challenges that a global clinical and genomic data-sharing approach presents, suggest potential solutions and highlight key initiatives (some of which are sponsored by GA4GH) to foster these activities in the molecular-profiling landscape ( Table 1) .
Challenges in data sharing
In recognition of the urgent need to generate and maximize the value of high-throughput molecular data in cancer research, international efforts such as The Cancer Genome Atlas (TCGA) 10 and the International Cancer Genome Consortium (ICGC) 11 were established to unify genomics-driven research efforts. Although these initiatives were groundbreaking and laid the foundation for future opportunities, the utility of data sharing can only be maximized once its scope is extended beyond information derived solely from tumor samples collected at a single time point and without clinical correlates (as was the case with initiatives such as TCGA and ICGC). Ideally, attendant clinical data would include a longitudinal series of samples with detailed clinical, genomic and pathological information 12 . The analysis of a single tumor sample per patient can cause researchers to inadvertently ignore the phenomena of tumor heterogeneity and clonal evolution, and it obscures the dynamics of disease progression at both the clinical and molecular levels 13 . In most cases, longitudinal data, including clinical co-morbidities, and the effects of different medications and environmental exposures, are required for a granular assessment that enables the identification of correlates for favorable or poor clinical outcome, and of patient-specific de novo resistance mechanisms under treatment pressure. However, longitudinal data with detailed clinical and pathological information are more difficult to harmonize and share between institutions.
Clinical data: challenges and potential solutions The data in most electronic health-record (EHR) systems are not vetted for quality assurance and are not structured in a way that readily enables easy extraction. These problems are magnified when we attempt to extract and compare data across institutions, and they become substantial barriers to cross-border data-sharing initiatives.
In contrast to rare diseases, for which initiatives such as Human Phenotype Ontology 14, 15 , PhenoTips 16 and PhenoDB 17 have underpinned the development of a standardized human-phenotypic ontology, the cancer field lacks a universally accepted lexicon. Tools such as the PheWAS (developed from the Vanderbilt-led Phenome-Wide Association Study) were developed to facilitate unbiased interrogation of the EHR to detect associations between a specific genetic variant and a wide range of clinical outcomes and phenotypes 18 . Although the PheWAS and similar tools have been applied thus far
Box 1 Hypothetical examples illustrating importance of data sharing
Hypothetical examples 1. A group from country A employed a targeted panel to assess a selected set of hot-spot mutations in 50 genes and published these results on the basis of an analysis of 1,000 patients with colorectal cancer. A group in country B, capable of performing whole-exome sequencing, has identified that one of these hot spots, in the presence of another specific mutation, may adversely affect clinical outcome in colorectal cancer. To confirm their hypothesis, the country B group would like to collaborate with the group in country A to determine whether remaining DNA samples and clinical data can be shared. 2. A research group from country A reported favorably on a variant in gene X that may predict response for drug Y. Their findings indicated that the variant is significantly associated with progression-free survival at 6 months after the initiation of treatment. A group from country B investigated the same gene variant for the same drug, but found no statistical relationship at 3 months and 24 months after treatment initiation. A research group from country C now wants to perform a meta-analysis to determine whether the findings of both trials are in agreement, but it requires the original and individualized clinical and genomic data from the groups in countries A and B. 3. Two large studies have recently been published suggesting that the use of drug Z may confer a better prognosis in breast cancer among patients who have a common somatic variant. There are many large oncology practices worldwide that capture the use of drug Z in their patients' EHRs. Can this information be collected and integrated to provide a reliable validation of this finding? 4. One of 500 patients in a clinical trial in country A responded to drug X, and this patient's tumor is known to harbor a rare germline variant. A large institution in country B is currently considering running a similar trial for the same drug. The sharing of the details of such incidental findings would have an important bearing on the new trial.
Box 2 Description of GA4GH
GA4GH is a not-for-profit worldwide alliance of more than 380 international stakeholders from 38 countries, with a current focus on rare diseases and cancer 30 and an emerging interest in infectious disease. GA4GH operates through a series of Working Groups (WG): Data WG, Regulatory and Ethics WG, Security WG and Clinical WG, which develop initiatives, policies, recommendations and application-program interfaces (APIs) that promote and harmonize responsible and effective data sharing. Although GA4GH produces recommendations, it does not seek to enforce data standards, but rather to persuade potential stakeholders of the added value of a collaborative data-sharing culture. The first plenary meeting of GA4GH stakeholders took place in March 2014 at the Wellcome Trust in London, UK, with subsequent conferences in San Diego, California, USA, and Leiden, the Netherlands. This Perspective was undertaken after discussions during the third GA4GH plenary meeting in Leiden, and in response to a number of international data-sharing initiatives (including the recently launched AACR's transatlantic data-sharing project GENIE 68 ).
npg p e r s p e c t i v e Table 1 Key cancer-molecular-profiling and big-data initiatives, including GA4GH-enabled initiatives
Examples of initiatives
Description a How is this initiative enabling data sharing?
National and international molecular-screening platforms SPECTA (screening patients for efficient clinical trial access) 64 SPECTA represents a pan-European collaboration that involves more than 40 clinical centers in 16 European countries, which had an initial focus on colorectal cancer but is now expanding to various other tumor types.
• Molecular-screening platform that matches patients' genomic profiles to potential clinical trials
Precision-medicine clinical trials
National Cancer Institute's Molecular Analysis for Therapy Choice (NCI-MATCH) 65 A complex basket trial evaluating a new or existing agent against a specific molecular aberration across tumor types. NCI-MATCH will be available at more than 2,400 clinical sites across the US.
• Enables sharing of clinical and genomic data to facilitate access to innovative targeted therapies Targeted Agent and Profiling Utilization Registry (TAPUR) 66 and Drug Rediscovery Protocol (DRUP)
In these two trials, genomic analysis identifies a particular abnormality that allows patients access to a molecularly targeted agent already shown to be effective against this "actionable" mutation in at least one cancer.
• Intercontinental, parallel data-sharing approach to facilitate patient access to "approved" treatments
Big-data initiatives
The Cancer Genome Atlas (TCGA) 10 An NCI-NHGRI collaboration that has generated comprehensive catalogs of the key genomic changes in major types and subtypes of cancer.
• Supports open access to genomic data International Cancer Genome Consortium (ICGC) 11 and ICGCMed b
A consortium created to coordinate large-scale, comprehensive molecular characterization of 50 different tumor types and/or subtypes. ICGCMed is the next generation project of ICGC, with a stated aim to link genomic data with longitudinal clinical data.
• Supports open access to data
• Links genomic and clinical data/outcomes (ICGCMed)
Cancer Core Europe (CCE) 67 A consortium of six European cancer centers that share a common translational genomic platform to conduct next-generation clinical trials.
• Establishes a European virtual e-cancer hospital 100,000 Genomes Project 3 A project supported by Genomics England to sequence 100,000 whole genomes, with a focus on rare diseases, cancer and infectious diseases.
• Enables sharing of clinical and WGS data for clinical actionability
CancerLinQ 20 An ASCO-led initiative to create a data-informatics system that will collect, analyze and learn from complete EHRs, with the primary goal of improving the quality of care provided to people with cancer.
• Enables sharing of clinical and genomic data
• Addresses data security and access issues
The Cancer Genome Collaboratory A Canadian NSERC, Genome Canada and CIHR-supported initiative to make ICGC data available for cloud computing in a community cloud infrastructure (http://www.genomecanada.ca/en/cancer-genome-collaboratory).
• Enables sharing of clinical and genomic or NGS data
• Co-locates compute with big data sets Genomics Evidence Neoplasia Information Exchange (GENIE) 68 An AACR-enabled transatlantic initiative to integrate genomic profiles and longitudinal clinical outcomes at seven different cancer centers in the US, Canada and Europe.
GA4GH-enabled data-sharing initiatives
BRCA challenge b A global initiative to pool data on BRCA1/2 genetic variants and corresponding clinical data (http://www.genomicsandhealth.org/work-products-demonstrati on-projects/brca-challenge-0).
• Creates a curated catalog, BRCA Exchange Beacon Project b A simple, online web service that allows users to query an institution's databases to determine whether they contain a genetic variant of interest (http://www. genomicsandhealth.org/work-products-demonstration-projects/beacon-project-0).
• Enables sharing of genetic data Matchmaker Exchange b A collaborative effort to facilitate the matching of cases with similar phenotypic and genotypic profiles through standardized APIs (http://www.genomicsandhealth. org/work-products-demonstration-projects/matchmaker-exchange-0).
• Establishes federated platforms through standardized APIs
Other data sharing or harmonization initiatives BD2K (big data to knowledge) 26,b A trans-NIH program to support the development of innovative approaches and tools to maximize and accelerate the integration of data science into biomedical research.
• Develops new methods and standards for sharing genomic information Electronic Medical Records and Genomics (eMERGE) 19 A national network that combines DNA biorepositories with EHR systems for large-scale, high-throughput genetic research.
• Finds solution to link EHR data to genomic data Genome Data Commons (GDC) An interactive knowledge system to store, analyze and distribute cancergenomics data generated by NCI and other research organizations (http://www. cancer.gov/news-events/press-releases/2014/GenomicDataCommonsNewsNote).
• Finds solution to data warehousing Helix Nebular Project A European partnership between information-technology providers and research centers that aims to develop a science cloud to meet the growing demand for computing power (http://www.helix-nebula.eu).
• Enables sharing of clinical and genomic data through cloud computing Health Level 7 International (HL7) and fast healthcare interoperability resources (FHIR)
An international collaboration dedicated to providing frameworks and standards for the exchange, sharing and integration of electronic health information (http://www.hl7.org/fhir/).
• Develops standards for sharing EHR data ICGC-TCGA dialogue for reverseengineering assessments and methods (DREAM) 28,b An international effort to improve standard methods for identifying cancerassociated mutations and rearrangements in WGS data.
• Standardizes WGS and bioinformatics algorithms mainly to germline genetic diseases, as in initiatives conducted by the Electronic Medical Records and Genomics (eMERGE) Network 19 , they could potentially support similar approaches in somatic diseases such as cancer. The tracking of longitudinal clinical outcomes is crucial to linking clinical and molecular data for prognostic or predictive relevance; however, efficacy outcomes (such as objective responses and time to disease progression based on validated criteria, and overall survival) and toxicity information (as classified by the National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) are not routinely captured in patient EHRs outside the context of clinical trials.
Solutions to these clinical-data challenges are at a less mature stage than are the solutions for genomic data, but they are developing. Standards are emerging for how to represent data from EHRs in a way that can be shared between institutions. Leading among these is the international fast healthcare interoperability resources effort (FHIR) (http://www.hl7.org/fhir/), which is being developed in conjunction with the Health Level 7 International (HL7) infrastructure. Technical tools are now emerging that use standards such as the FHIR to federate data from EHRs in a functional way that can perform aggregation, cleaning and parsing of data longitudinally over time and from multiple disparate sources. It is crucial that in such activities, the quality of the merged data is assured and controlled. A key example of such an effort is CancerLinQ 20 , a system that the American Society of Clinical Oncology (ASCO) is custom-building to gather data through direct electronic feeds from numerous oncology practices. CancerLinQ aims to measure, monitor and learn through the analysis of pooled information to improve the quality of cancer care and to provide clinical-decision support.
The tools described above require well-developed and widely accepted ontologies or vocabularies to standardize the classification of diseases; examples of these include the International Classification of Diseases (ICD) (http://www.who.int/classifications/icd/en/) and the Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) (http://www.nlm.nih.gov/snomed/). In an effort to resolve the lack of standardized phenotypic-variation descriptors in malignancy, particularly in the genomic era, a task team of the GA4GH Clinical Working Group is developing approaches to support the alignment of and mapping across ontologies in cancer by leveraging specialist resources, such as those provided by the National Cancer Institute Thesaurus 21 and the Human Phenotype Ontology 14, 15 .
Genomic data: challenges and potential solutions Genomic-data sharing in cancer research has been successful within large consortia such as TCGA and the ICGC. Databases such as the Cancer Genomics Hub (CGHub), the European Genome-Phenome Archive, and the ICGC data portal provide cancer genomics data to researchers at a rate of multiple petabytes per month-representing the largest exchange of genomic information in any area of research 22 . New databases, such as the Genome Data Commons (GDC) of the NCI (USA) (created as part of the development of a Precision Cancer Medicine knowledge system; http://www.cancer.gov/news-events/ press-releases/2014/GenomicDataCommonsNewsNote) and the 100,000 Genomes Project (UK) 3 , are being constructed. However, these systems are not designed to handle data generated on a scale of millions of samples, as is anticipated with widespread clinical application of NGS. This is an entirely new data-engineering challenge.
Most cancer-genomics data generated by clinical applications are held separately in silos by different medical institutions or by their contractors. This makes aggregated data analysis more difficult. Because the data sets are large, now consisting of multiple petabytes (10 15 bytes), a simple transmission of genome-sequencing data between geographically remote repositories is increasingly infeasible.
The aggregation problem is made more difficult by substantial heterogeneity in the procedures for data collection, storage and representation. Problems of data size can be overcome by sharing only the mutation and gene-expression information from the clinical samples, and not the raw data produced by sequencing machines. However, a lack of consensus in the mutation-calling process, in the methods for gene-expression quantification and even in the data formats used to express this information is hampering current aggregation efforts. Nonstandardized ad hoc functional annotation and a lack of consensus between institutions on the clinical importance of genomic variants further limit the universal applicability of NGS data for guiding improvements in patient care 8 . In particular, there are no widely accepted definitions of driver mutations in cancer and "clinically actionable" results 23, 24 . This represents a serious barrier to the integration of clinical genomics into healthcare delivery.
Solutions presented by the GA4GH
In response to these diverse challenges, collaborative efforts, including GA4GH-enabled initiatives, have proposed 25 and/or are implementing multiple solutions. Recognizing the need to link diverse genomicdata repositories, the GA4GH Data Working Group, in collaboration with initiatives such as the US National Institutes of Health (NIH) Big Data to Knowledge (BD2K) Center in Translational Genomics 26 , are pioneering new standards and methods for sharing genomic information. They are developing a universal application-programming interface (API) that will facilitate the creation of a global, cohesive genome-informatics ecosystem, which would maximize data sharing at scale. Specific task teams within the GA4GH Data Working Group are implementing particular functionalities in the GA4GH API to enable expressive and universal representation of genetic variation; gene and transcript expression; annotation of genomics features; and relationships between genotype and phenotype.
Furthermore, to facilitate the harmonization of mutation-calling procedures among institutions, the ICGC and TCGA invited the cancer-genomics and bioinformatics communities to work together to identify the best pipelines for the detection of mutations in DNA-sequencing reads for cancer genomes 27 . This has led to the establishment of the ICGC-TCGA dialogue for reverse-engineering assessments and methods (DREAM) somatic mutation calling challenge ('the SMC-DNA meta-pipeline challenge'), a crowdsourced benchmark of somatic-mutation detection algorithms 28 . The Benchmarking Task Team of the GA4GH Data Working Group is working closely with the DREAM teams to identify the most effective algorithms for widespread use by the scientific and clinical community. The need to identify and share the best data-analysis pipelines has also stimulated considerable work on so-called containerized computation in genomics. In this approach, the development of code that executes different programs for data processing, analysis and interpretation facilitates easier exchange between different institutions and different computing environments than was previously possible. This would be analogous to the strategy used by the company Docker, in which shipping containers across the world's ports are standardized so that one set of machinery is sufficient at any port to handle any shipping container. In containerized computing, one type of packaging for data and programs enables analysis of the data on all computing systems. The Containers and Workflows Task Team of npg p e r s p e c t i v e the GA4GH Working Group is devoted to this area. Furthermore, containerized code that has been battle-tested in the DREAM challenges and by large consortium efforts is now being applied to clinical NGS analysis in cancer-a strategy proposed by groups such as the next-generation sequencing standardization of clinical testing (Nex-StoCT) II informatics work group for the analysis of germline variations in disease 29 .
With regard to the lack of consensus on what constitutes an "actionable" mutation, GA4GH is driving the Actionable Cancer Genome Initiative (ACGI) 30 . The main goals of the ACGI are to identify a list of "actionable" genes in different cancers with canonical targetable mutations, as well as rare variants of uncertain importance, and to aggregate data related to these aberrations-their evidence-based curated actionability calls and phenotypic or clinical information (including longitudinal data)-in a searchable format to enhance patient care.
Data-warehousing and data-access challenges
One question that members of the GA4GH have considered in detail is whether the world's genomic and clinical information will reside in a single physical database, or whether it will be made available through a federated network that spans a series of interlinked data repositories in many countries. Although both approaches have their supporters, GA4GH is investigating how a federated model (which may involve a relatively small number of large databases) could be organized to fulfill data-warehousing requirements, while supporting improved data access for data consumers. In a federated system, some data are likely to be on commercial clouds (for example, Amazon, Google, Microsoft or one of the 30 cloud providers in the Helix Nebula Marketplace associated with Europe's Helix Nebula Project; http://www.helix-nebula. eu/) and the rest on government clouds, private clouds or other dedicated systems. The recent decision by the NIH to allow private and commercial cloud-computing solutions to be applied to the storage and analysis of the vast genomic data that is housed in its repositorythe database of Genotypes and Phenotypes (dbGaP) 31 -is timely. It opens up competition between different cloud solutions in genomics. The creation of a competitive market for such cloud solutions will enable secure and organized data storage at low cost, with sufficient elasticity to provide a dynamic platform that ensures rapid and efficient analysis of large data sets 32 (http://www.genomicsandhealth. org/working-groups/our-work/cloud-security).
Optimized, interoperable technical standards are needed for the analysis of data that are distributed across multiple sites, as suggested above. Beyond the data-harmonization challenges, there are also substantial technical challenges to ensuring coordinated version control; data uniqueness and integrity; location transparency; harmony and efficiency in access procedures; privacy and security requirements; and to maintaining compliance with institutional and legal regulations at the regional, national and international levels.
Furthermore, in conjunction with the GA4GH's API-based standardization efforts (as well as its file-based standards efforts), the Containers and Workflows Task Team of the GA4GH's Data Working Group is developing mechanisms that will allow a computational procedure to be ported to different institutions, where it can be run locally with reliably consistent results and minimal customization required. This allows a single institution to perform complex analysis of large data sets at remote sites. On the other hand, when only smaller data items are needed from a remote site, these can be obtained with a simple Internet query, again by using the API. A mechanism for queries of this type is in development by the GA4GH Beacon Project (http://www.genomicsandhealth.org/ work-products-demonstration-projects/beacon-project-0) ( Table 1) . Having a range of solutions such as these to data-aggregation and analysis problems is critical to the success of a federated system. Ethical, regulatory and security challenges Even if technical challenges are addressed, global data sharing will require a marked shift in the conventional ethics framework, especially given diversity in countries' legal and regulatory requirements. We may have reached the limits of applying current informed-consent procedures with an increased data-sharing culture that is posing new consent-related challenges (Box 3). Broad consent is a practical, overarching solution, although this practice can be contentious if it is not accompanied by proper governance 33 . Because informed consent is usually conducted as a once-off task, respect for individual autonomy demands ongoing oversight to respect the trust of participants who give researchers the right to use their data and samples for "future unspecified research." To ease these concerns, new variations of consent documents have been proposed (for example, tiered or dynamic consent and open consent) [33] [34] [35] [36] [37] , and novel governance models have been suggested 38 . It is important that the consent model chosen correspond to the nature of the study. Thus, broad consent is particularly suited for longitudinal studies (for example, UK Biobank; http://www. ukbiobank.ac.uk/), and open consent for those who wish to put their genome data in the public domain (for example, Personal Genome Project; http://www.personalgenomes.org/).
However, challenges to the development of consent procedures remain. For example, it is not possible to implement the rights of the individual to withdraw their archived data in an international study if data are anonymized 39 . In addition, it is even more challenging to protect participants' privacy, given the unique identifying
Box 3 Consent models for biomedical research
In all situations indicated below, the principles of respect for the individual 'data donor' and ethically responsible data sharing are implicit to the process. Specific consent In this situation, consent is limited to data generated from a particular research protocol, applied for a specific disease type. Specific and "related conditions" consent This consent process adds the possibility for the consent for use of research data to be extended to other, related disease domains.
Tiered consent
Here a series of options is provided, with the research participant being able to indicate consent for one, some or all of the options indicated. Dynamic consent This is a continuous consent process, with the opportunity for the participant to indicate their consent (or lack of consent) for their data to be used in an evolving series of research studies that develops over time from the original research protocol. Broad consent This indicates consent for future unspecified research studies, whose ethical principles are ensured through oversight from an independent research-ethics committee.
Open consent
For an open consent model, all future biomedical research is indicated, with resulting research data becoming accessible to other researchers. nature of genetic information [40] [41] [42] [43] . Germline data collection (whether preplanned or incidentally detected) increases the complexity, if researchers have promised to re-contact individuals to notify them particularly if new genetic findings come to light after original use. Further complicating matters, conventional national or institutional review boards may not have the expertise to assess the risks and compliance regulations that are associated with international datasharing projects, and current oversight systems are, in many cases, not adequately equipped for privacy breaches 44 .
The GA4GH has approached these complex issues from a fundamental human-rights perspective, by proposing and adopting a Framework for Responsible Sharing of Genomic and Health-Related Data that emphasizes both the rights of all citizens to benefit from the advances of science and the rights of scientists to be recognized for their work 45 . This approach is complementary to and bolsters conventional bioethics principles, but employing a legal humanrights perspective embeds responsible clinico-genomic data sharing within a recognized and endorsed international legal framework. The approach thus provides an environment in which the ethics principles espoused by this Framework can be recognized and adhered to by all stakeholders. This Framework can also foster responsible data sharing more strongly than a conventional bioethics approach by offering legal protection in several areas, such as privacy; anti-discrimination and fair access; and procedural fairness 44 .
It will require an ethics and regulatory framework that fosters cross-border, collaborative, open data sharing to address the complex issues highlighted above. Given the substantial legal and ethical variations between different countries and/or jurisdictions, there is an urgent need for harmonization. To that end, the implementation of the GA4GH Framework 46 will enable responsible data sharing, while still respecting individual rights. The adoption of and adherence to the following GA4GH-enabled principles, policies and tools within the Framework will provide a blueprint for addressing the complex ethical, legal and security issues outlined.
As an overarching enabler of the activities and human-rights aspirations outlined above, the GA4GH Framework underpins all aspects of its genomic and clinical data-sharing activities going forward. As part of this framework, the GA4GH Regulatory and Ethics Working Group produced a 'GA4GH Consent Policy' 47 , which balances the need to respect the autonomous decision-making rights of each individual patient with the promotion of the common good of international genomic and health-related data sharing. Three consent tools 48 GA4GH's Regulatory and Ethics Working Group has prepared a 'Privacy and Security Policy' 49 that requires a proportionate approach, which involves weighing the real risks and benefits, as well as a concordance of terms such as pseudonymized; de-identified; coded, etc., to address the "Babel" of nomenclature 50 . GA4GH's Regulatory and Ethics Working Group has also published a "safe harbor" mechanism for privacy protection 44 in cross-border sharing, which elucidates the criteria for mutually agreed-upon data-protection principles 25 . To specifically address privacy and security mechanisms, the GA4GH Figure 1 Data-sharing vision as facilitated by GA4GH through its working groups, each of which focuses on particular data-sharing challenges: for example, Clinical Working Group, establish common data elements; Data Working Group, establish universal API standardization; Regulatory and Ethics Working Group, harmonize ethics processes; Security Working Group, establish data-access procedures. GA4GH provides guidance to facilitate responsible, effective and secure data sharing. Groups such as hospitals, institutes and pharmaceutical companies that are conducting data-generating initiatives are encouraged to share clinical and genomic information under the framework developed by GA4GH, including collaborations with third-party researchers via robust access procedures.
npg p e r s p e c t i v e Security Working Group has created a Security Infrastructure Policy Paper 51 that documents the standards and implementation practices for protecting the privacy and security of shared genomic and clinical data. For cases in which the data are highly phenotypic-that is, there are sufficient data elements that, either alone or in combination with other information, could serve to re-identify an individual-a form of a controlled-access approach may be the most appropriate, such as the one used by the Data Access Compliance Office in the ICGC 7 . GA4GH is, however, considering the potential of a registered system of access for less-sensitive data as an intermediary tier between closed and open access.
It is also extremely important to ensure ethics compliance and responsible conduct by researchers. To this end, the GA4GH's Regulatory and Ethics Working Group has developed an accountability policy 52 . Additionally, the ethical standards associated with the commercial usage and sale of aggregated, anonymized data are unclear and will require consideration. In addition, it is crucial to educate the cancer community at large to ensure the responsible use and sharing of clinical and genomic information 53 .
Concluding remarks
The development of responsible and effective practices for sharing genomic and clinical data that are generated from biospecimens is increasingly important for patients (including those who have cancer), as it enables research discoveries to be applied rapidly for their benefit. Patients are actively pursuing approaches that ensure their rights to share information for the overall benefit of citizens and societies 54, 55 . A European survey conducted in 2012 of 811 individuals with cancer revealed that more than 91% of patients wanted their samples to be retained for future research, and a substantial number of them also indicated that they would participate in biomarker testing to enable personalization of their treatment 56 . More recently, a survey of 100 people with breast cancer indicated that more than 75% of them would share de-identified data with researchers not involved in their care, and that 60% of patients were additionally prepared to share identified data 57 . As a follow up to these studies, the GA4GH is collaborating with a number of institutions and prominent patient-advocacy groups to develop a survey to measure the specific attitudes of individuals with cancer to the sharing of genomic and/or clinical data.
Patients with cancer are emphasizing that they no longer want to be passive recipients but are increasingly active participants in both high-quality research and its clinical adoption; these principles are enshrined in the European Cancer Patients Bill of Rights 58, 59 , which was launched in the European Parliament on World Cancer Day 2014. Substantial challenges in relation to the privacy of data exist, particularly in Europe, in the context of both the Clinical Trials Directive (http://www.ec.europa.eu/health/human-use/clinical-trials/directive/ index_en.htm) and the recently approved General Data Protection Regulation 60 . However, patients are increasingly recognizing the value of genomics research, its clinical translation 61 and the need for responsible data sharing 62 . That said, issues such as discrimination must be addressed adequately and with clear patient education and input 62, 63 , not only in terms of their access to optimal-quality care (including precision cancer care) but also in relation to socio-economic factors such as employment rights and the availability of affordable insurance; without such attention, their enthusiasm for participating in genomics research and for acting as advocates for responsible data sharing may waver. Individuals with cancer generally have a positive attitude to sharing their data (http://www.free-the-data.org/); we need to ensure that data sharing happens in a timely, responsible and effective manner, so that its value in improving health care can be realized as rapidly as possible.
The GA4GH is committed to engaging with key stakeholders, including researchers, healthcare professionals and patients with cancer, to establish a globally effective genomic and clinical datasharing ecosystem that addresses the diverse challenges that we have articulated in this Perspective (Fig. 1). GA4GH's success in fostering "a coalition of the willing" within the international community, in combination with its ability to develop and implement technical informatics solutions within a harmonized and secure ethical and legal framework, can help to deliver a powerful, globally accessible clinico-genomic platform and to foster an associated philosophy that supports data-driven advances for patients and societies. p e r s p e c t i v e nature medicine VOLUME 22 | NUMBER 5 | MAY 2016
